NSG
CRSP icon

Nalls Sherbakoff Group’s CRISPR Therapeutics CRSP Stock Holding History

Nalls Sherbakoff Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$157 Hold
3
– – ﹤0.01% 435
2025
Q3 		$194 Hold
3
– – ﹤0.01% 420
2025
Q2 		$146 Sell
3
-4
-57% -$155 ﹤0.01% 423
2025
Q1 		$238 Buy
+7
New +$297 ﹤0.01% 424
2023
Q4 		$439 Hold
7
– – ﹤0.01% 420
2023
Q3 		$318 Hold
7
– – ﹤0.01% 442
2023
Q2 		$449 Hold
7
– – ﹤0.01% 457
2023
Q1 		$310 Buy
+7
New +$340 ﹤0.01% 495

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return